US 12,215,087 B2
Inhibitors of NLRP3 inflammasome
George Hartman, Lansdale, PA (US); Paul Humphries, Menlo Park, CA (US); and Kevin Edward Leif Wilhelmsen, Albany, CA (US)
Assigned to BioAge Labs, Inc., Richmond, CA (US)
Filed by BioAge Labs, Inc., Richmond, CA (US)
Filed on Jul. 17, 2023, as Appl. No. 18/353,422.
Application 18/353,422 is a continuation of application No. 17/701,856, filed on Mar. 23, 2022, granted, now 11,702,391.
Claims priority of provisional application 63/164,780, filed on Mar. 23, 2021.
Claims priority of provisional application 63/219,538, filed on Jul. 8, 2021.
Prior Publication US 2024/0067610 A1, Feb. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 231/56 (2006.01); C07D 235/06 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01)
CPC C07D 231/56 (2013.01) [C07D 235/06 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01)] 6 Claims
 
1. A compound that is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.